Dihydroergotamine Nasal Spray [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2019-06-26 14:47 (1957 d 08:55 ago) – Posting: # 20363
Views: 2,987

Hi all,


❝ ❝ If it is required, …


❝ It is. If you would deviate from a guidance without a controlled correspondence you risk an RtR.


It would be an interesting lawsuit, if the company gets an RtR for lack of baseline correction and sues the FDA because the formal requirement is meaningless.
Perhaps a case where FDA could hide behind the fact that it is a draft and contains nonbinding recommendations blahblah?

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,280 posts in 4,889 threads, 1,655 registered users;
72 visitors (0 registered, 72 guests [including 9 identified bots]).
Forum time: 22:42 CET (Europe/Vienna)

Freedom is always and exclusively
freedom for the one
who thinks differently.    Rosa Luxemburg

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5